Amedisys Inc. (NASDAQ:AMED) shares traded -3.72% lower at $78.97 on Wall Street last session.
In accordance with the data, 16 analysts cover Amedisys Inc. (NASDAQ:AMED). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $130.00 and a low of $84.00, we find $111.00. Given the previous closing price of $82.02, this indicates a potential upside of 35.33 percent. AMED stock price is now -12.24% away from the 50-day moving average and -22.95% away from the 200-day moving average. The market capitalization of the company currently stands at $2.57B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 6 analysts and a buy by 8. Brokers who have rated the stock have averaged $109.54 as their price target over the next twelve months.
With the price target of $93, Barclays recently initiated with Equal Weight rating for Amedisys Inc. (NASDAQ: AMED)., while ‘UBS’ rates the stock as ‘Sell’.
In other news, North Michael Paul, Chief Information Officer sold 5,908 shares of the company’s stock on Mar 03. The stock was sold for $510,628 at an average price of $86.43. Upon completion of the transaction, the Chief Information Officer now directly owns 4,164 shares in the company, valued at $0.33 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23, Chief Compliance Officer Bohnert Denise M. sold 557 shares of the business’s stock. A total of $64,055 was realized by selling the stock at an average price of $115.00. This leaves the insider owning 11,850 shares of the company worth $0.94 million. Insiders disposed of 18,342 shares of company stock worth roughly $1.45 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMED stock. A new stake in Amedisys Inc. shares was purchased by OCCUDO QUANTITATIVE STRATEGIES LP during the first quarter worth $2,650,000. EXODUSPOINT CAPITAL MANAGEMENT, LP invested $2,344,000 in shares of AMED during the first quarter. In the first quarter, JUMP FINANCIAL, LLC acquired a new stake in Amedisys Inc. valued at approximately $2,073,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in AMED for approximately $1,953,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in AMED valued at around $1,900,000 in the second quarter. In total, there are 400 active investors with 98.28% ownership of the company’s stock.
Amedisys Inc. (NASDAQ: AMED) opened at $81.00 on Tuesday. During the past 12 months, Amedisys Inc. has had a low of $79.30 and a high of $179.91. As of last week, the company has a debt-to-equity ratio of 0.41, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for AMED is $89.89 and a two-hundred day moving average price translates $102.32 for the stock.
The latest earnings results from Amedisys Inc. (NASDAQ: AMED) was released for Sep, 2022. According to the Medical Care Facilities Company, earnings per share came in at $1.15, missing analysts’ expectations of $1.22 by -0.07. This compares to $1.04 EPS in the same period last year. The net profit margin was 5.30% and return on equity was 11.80% for AMED. The company reported revenue of $562.06 million for the quarter, compared to $559.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.49 percent. For the current quarter, analysts expect AMED to generate $563.59M in revenue.
Amedisys Inc.(AMED) Company Profile
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
